Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 18/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19208547 | 0.91 | CFD (0.38) | CFDMAPT | |
| SCHEMBL25097651 | 0.90 | CFD (0.41) | CFDMAPT | |
| SCHEMBL20334215 | 0.85 | CFD (0.39) | CFD | |
| SCHEMBL29545721 | 0.85 | HDAC8 (0.41) | CFDMAPT | |
| SCHEMBL17025123 | 0.85 | HDAC8 (0.41) | CFDMAPT | |
| SCHEMBL18649190 | 0.85 | CFD (0.35) | CFDMAPT | |
| SCHEMBL19236949 | 0.85 | CFD (0.40) | CFDSYK | |
| SCHEMBL29781727 | 0.84 | CFD (0.40) | CFDSYK | |
| SCHEMBL17023675 | 0.84 | CFD (0.40) | CFDSYK | |
| SCHEMBL19208779 | 0.83 | PFKFB2 (0.37) | CFDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-3925956-B1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-07-13 | — | — | US | disclosed |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-07-13 | — | — | US | disclosed |
| US-11559515-B2 | Indole compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-115490751-A | Factor D inhibitors | 拜奥克里斯特制药公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-109121414-B | Benzopyrazole compounds and analogs thereof | 拜奥克里斯特制药公司 | 2022-07-05 | — | — | CN | disclosed |
| EP-3411411-B3 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3925956-A1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BioCryst Pharmaceuticals, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3411411-B1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-9598446-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598446-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2017035351-A1 | AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| EP-3110417-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015130806-A9 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| WO-2015130806-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130806-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | C5, DPYD, C9 | CFD 40/4885SYK 391/4885MAPT 3029/4885 |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | C9, C5, C1QBP | CFD 13/4885SYK 418/4885MAPT 2793/4885 |
| US-11559515-B2 | Indole compounds and analogues thereof | C5, IDO1, IDO2 | CFD 25/4885SYK 504/4885MAPT 1382/4885 |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | CFD 1/4885SYK 491/4885MAPT 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.